Chen Yin, Lin Lei, Agyekum Isaac, Zhang Xing, St Ange Kalib, Yu Yanlei, Zhang Fuming, Liu Jian, Amster I Jonathan, Linhardt Robert J
College of Food and Pharmacy, Zhejiang Ocean University, Zhoushan, Zhejiang 316000, China; Department of Chemistry and Chemical Biology, Center for Biotechnology and Interdisciplinary Studies, Rensselaer Polytechnic Institute, Troy, New York 12180; Department of Biology, Center for Biotechnology and Interdisciplinary Studies, Rensselaer Polytechnic Institute, Troy, New York 12180; Department of Chemical and Biological Engineering, Center for Biotechnology and Interdisciplinary Studies, Rensselaer Polytechnic Institute, Troy, New York 12180; Department of Biomedical Engineering, Center for Biotechnology and Interdisciplinary Studies, Rensselaer Polytechnic Institute, Troy, New York 12180.
Department of Chemistry and Chemical Biology, Center for Biotechnology and Interdisciplinary Studies, Rensselaer Polytechnic Institute, Troy, New York 12180; Department of Biology, Center for Biotechnology and Interdisciplinary Studies, Rensselaer Polytechnic Institute, Troy, New York 12180; Department of Chemical and Biological Engineering, Center for Biotechnology and Interdisciplinary Studies, Rensselaer Polytechnic Institute, Troy, New York 12180; Department of Biomedical Engineering, Center for Biotechnology and Interdisciplinary Studies, Rensselaer Polytechnic Institute, Troy, New York 12180.
J Pharm Sci. 2017 Apr;106(4):973-981. doi: 10.1016/j.xphs.2016.11.023. Epub 2016 Dec 20.
Heparin is a polysaccharide that is widely used as an anticoagulant drug. The mechanism for heparin's anticoagulant activity is primarily through its interaction with a serine protease inhibitor, antithrombin III (AT), that enhances its ability to inactivate blood coagulation serine proteases, including thrombin (factor IIa) and factor Xa. The AT-binding site in the heparin is one of the most well-studied carbohydrate-protein binding sites and its structure is the basis for the synthesis of the heparin pentasaccharide drug, fondaparinux. Despite our understanding of the structural requirements for the heparin pentasaccharide AT-binding site, there is a lack of data on the natural variability of these binding sites in heparins extracted from animal tissues. The present work provides a detailed study on the structural variants of the tetrasaccharide fragments of this binding site afforded following treatment of a heparin with heparin lyase II. The 5 most commonly observed tetrasaccharide fragments of the AT-binding site are fully characterized, and a method for their quantification in heparin and low-molecular-weight heparin products is described.
肝素是一种多糖,被广泛用作抗凝血药物。肝素抗凝血活性的机制主要是通过其与丝氨酸蛋白酶抑制剂抗凝血酶III(AT)相互作用,增强其灭活血液凝固丝氨酸蛋白酶的能力,包括凝血酶(因子IIa)和因子Xa。肝素中的AT结合位点是研究最深入的碳水化合物-蛋白质结合位点之一,其结构是合成肝素五糖药物磺达肝癸钠的基础。尽管我们了解肝素五糖AT结合位点的结构要求,但对于从动物组织中提取的肝素中这些结合位点的天然变异性缺乏数据。本研究对用肝素裂解酶II处理肝素后该结合位点的四糖片段的结构变体进行了详细研究。对AT结合位点最常观察到的5种四糖片段进行了全面表征,并描述了一种在肝素和低分子量肝素产品中对其进行定量的方法。